SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2024-08-28
Accession Number: 0001213900-24-073419
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390024073419/ea020832406ex1-1_synergy.htm

Chunk 4 of 15
Word Count: 1473
Character Count: 9443

Document Content:

Labor Relations Board, any state or local labor relation board or any foreign labor relations board, and no grievance or arbitration proceeding arising out of or under any collective bargaining agreement is so pending against the Company or any of its subsidiaries, or, to the Company’s knowledge, threatened against it and (B) no labor disturbance by the employees of the Company or any of its subsidiaries exists or, to the Company’s knowledge, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or its subsidiaries, principal suppliers, manufacturers, customers or contractors, that could reasonably be expected, singularly or in the aggregate, to have a Material Adverse Effect. The Company is not aware that any key employee or significant group of employees of the Company or any subsidiary plans to terminate employment with the Company or any such subsidiary.

(xiv) ERISA
Compliance. No “prohibited transaction” (as defined in Section 406 of the Employee Retirement Income Security Act of
1974, as amended, including the regulations and published interpretations thereunder (“ERISA”), or Section 4975 of
the Internal Revenue Code of 1986, as amended from time to time (the “Code”)) or “accumulated funding deficiency”
(as defined in Section 302 of ERISA) or any of the events set forth in Section 4043(b) of ERISA (other than events with respect to which
the thirty (30)-day notice requirement under Section 4043 of ERISA has been waived) has occurred or could reasonably be expected to occur
with respect to any employee benefit plan of the Company or any of its subsidiaries which would reasonably be expected to, singularly
or in the aggregate, have a Material Adverse Effect. Each employee benefit plan of the Company or any of its subsidiaries is in compliance
in all material respects with applicable law, including ERISA and the Code. The Company and its subsidiaries have not incurred and could
not reasonably be expected to incur liability under Title IV of ERISA with respect to the termination of, or withdrawal from, any pension
plan (as defined in ERISA). Each pension plan for which the Company or any of its subsidiaries would have any liability that is intended
to be qualified under Section 401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which
could, singularly or in the aggregate, cause the loss of such qualification.

(xv) Environmental
Matters. The Company and its subsidiaries are in compliance with all foreign, federal, state and local rules, laws and regulations
relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or
the environment which are applicable to their businesses (“Environmental Laws”). There has been no storage, generation,
transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other hazardous
substances by, due to, or caused by the Company or any of its subsidiaries (or, to the Company’s knowledge, any other entity for
whose acts or omissions the Company or any of its subsidiaries is or may otherwise be liable) upon any of the property now or previously
owned or leased by the Company or any of its subsidiaries, or upon any other property, in violation of any law, statute, ordinance, rule,
regulation, order, judgment, decree or permit or which would, under any law, statute, ordinance, rule (including rule of common law),
regulation, order, judgment, decree or permit, give rise to any liability, except for any violation or liability which has not had and
would not reasonably be expected to have, singularly or in the aggregate, a Material Adverse Effect; and there has been no disposal,
discharge, emission or other release of any kind onto such property or into the environment surrounding such property of any toxic or
other wastes or other hazardous substances with respect to which the Company or any of its subsidiaries has knowledge.

(xvi) SOX
Compliance. The Company is has taken all actions it deems reasonably necessary or advisable to take on or prior to the date of this
Agreement to assure that, upon and at all times after the effectiveness of the Registration Statement, it will be in compliance in all
material respects with all applicable provisions of the Sarbanes-Oxley Act of 2002 and all rules and regulations promulgated thereunder
or implementing the provisions thereof. (the “Sarbanes-Oxley Act”) that are then in effect and will take all action
it deems reasonably necessary or advisable to assure that it will be in compliance in all material respects with other applicable provisions
of the Sarbanes-Oxley Act not currently in effect upon it and at all times after the effectiveness of such provisions.

(xvii) Certain
Regulatory Matters. The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company
or its subsidiaries that are described or referred to in the Registration Statement, the Time of Sale Disclosure Package and the Final
Prospectus were conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including,
without limitation, those administered by the Food and Drug Administration of the U.S. Department of Health and Human Services (“the
FDA”) the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those
performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration
Statement, the Time of Sale Disclosure Package and the Final Prospectus are accurate and complete in all material respects and fairly
present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other
studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred
to in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. Except as described in the Registration
Statement, the Time of Sale Disclosure Package and the Final Prospectus, neither the Company nor its subsidiaries has received any notices
or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions
similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination
or suspension of such studies or tests. The Company has established and administers a compliance program applicable to the Company and
its subsidiaries, to assist the Company, its subsidiaries and their directors, officers and employees of the Company and its subsidiaries
in complying with applicable regulatory guidelines (including, without limitation, those administered by the FDA and any other foreign,
federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). Except as would
not be reasonably expected to result in a Material Adverse Effect, neither the Company nor any of its subsidiaries has failed to file
with the applicable regulatory authorities (excluding the FDA or any foreign, federal, state or local governmental or regulatory authority
performing functions similar to those performed by the FDA) any filing, declaration, listing, registration, report or submission that
is required to be so filed. Neither the Company nor any of its subsidiaries has failed to file with the FDA or any foreign, federal,
state or local governmental or regulatory authority performing functions similar to those performed by the FDA, any filing, declaration,
listing, registration, report or submission that is required to be so filed. All such filings were in material compliance with applicable
laws when filed and no deficiencies have been asserted by any applicable regulatory authority (including, without limitation, the FDA
or any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA)
with respect to any such filings, declarations, listings, registrations, reports or submissions.

(xviii) Money
Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action,
suit or proceeding by or before any Governmental Entity involving the Company or any of its subsidiaries with respect to the Money Laundering
Laws is pending or, to the knowledge of the Company, threatened. “Governmental Entity” shall be defined as any arbitrator,
court, governmental body, regulatory body, administrative agency or other authority, body or agency (whether foreign or domestic) having
jurisdiction over the Company or any of its subsidiaries or any of their respective properties, assets or operations.